2024

Axiom

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noreferrer noopener" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div> 
<p class="has-drop-cap">Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, demonstrated its robust financial health in the <a href="https://ir.thermofisher.com/investors/news-events/news/news-details/2024/Thermo-Fisher-Scientific-Reports-First-Quarter-2024-Results/" target="_blank" aria-label="first quarter of 2024 (opens in a new tab)" rel="noreferrer noopener nofollow" class="deco-link">first quarter of 2024</a>. <br><br>Despite a slight revenue decline of 3% to $10.34 billion from the previous year’s $10.71 billion, the company has shown a commendable increase in its GAAP diluted earnings per share (EPS), which grew by 4% to $3.46. <br><br>Furthermore, the adjusted EPS saw a 2% increase, reaching $5.11. This performance underscores Thermo Fisher’s ability to navigate the complexities of the market while continuing to deliver value to its stakeholders.</p> 
<p>Significant achievements, including launching innovative products like the Thermo Scientific<img src="https://s.w.org/images/core/emoji/14.0.0/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;"> Dionex<img src="https://s.w.org/images/core/emoji/14.0.0/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;"> Inuvion<img src="https://s.w.org/images/core/emoji/14.0.0/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;"> Ion Chromatography system and the Axiom<img src="https://s.w.org/images/core/emoji/14.0.0/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;"> PangenomiX Array marked the quarter. The company’s strategic capital deployment, highlighted by a $3.0 billion stock repurchase and an 11 percent dividend increase, reflects its strong financial position and confidence in future growth prospects.</p> 
<h3 id="thermo-fisher-scientific-beats-eps-and-revenue-expectations-in-q1">Thermo Fisher Scientific Beats EPS and Revenue Expectations in Q1</h3> 
<p>When comparing these results against market expectations, Thermo Fisher has outperformed in several key areas. Analysts had projected an <a href="https://tokenist.com/investing/how-to-value-a-stock/" rel="dofollow" class="deco-link">EPS</a> of $4.71 and a revenue of $10.16 billion for the quarter. The company surpassed revenue expectations by reporting $10.34 billion and significantly exceeded the EPS forecast with an adjusted figure of $5.11. <br><br>The company’s ability to exceed analysts’ expectations indicates its robust commercial execution and operational discipline. Introducing high-impact, innovative products and expanding its service offerings have been crucial to this achievement. </p> 
<div class="cta-referral"> 
 <img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async"> 
 <div class="cta-referral__text"> 
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noreferrer noopener nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p> 
 </div> 
</div> 
<h3 id="tmo-ups-full-year-revenue-and-adjusted-eps-guidance-for-2024">TMO Ups Full-Year Revenue and Adjusted EPS Guidance for 2024</h3> 
<p>Thermo Fisher has raised its full-year revenue and adjusted EPS guidance for 2024, reflecting more robust operational performance. The company now expects revenue to be $42.3 to $43.3 billion, from the previous guidance of $42.1 to $43.3 billion. <br><br>Similarly, the adjusted EPS guidance has been raised to a new range of $21.14 to $22.02, up from the previous forecast of $20.95 to $22.00. This upward revision in guidance underscores the company’s confidence in its ability to continue delivering differentiated performance throughout the year.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe> 
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p> 
<h3 id="br"><br></h3> 
<p>The post <a rel="nofollow" href="https://tokenist.com/thermo-fisher-scientific-tmo-reports-q1-beat-with-5-11-eps-and-10-34-b-in-revenue/">Thermo Fisher Scientific (TMO) Reports Q1 Beat with $5.11 EPS and $10.34 B in Revenue</a> appeared first on <a rel="nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Thermo Fisher Scientific (TMO) Reports Q1 Beat with $5.11 EPS and $10.34 B in Revenue

Table of Contents

Tokenist

Other articles published on Apr 24, 2024

Cryptocurrencies To Buy and HODL For The Week

Top Performing Cryptocurrencies Today : Buy, Sell Or HODL ?

Make Your Crypto Work for You with EMCD Coinhold

New Solana Network Update Scheduled for Late May

Samourai Wallet Founders Face Federal Charges

May the Bull Run be with Bitcoin, ETF fever hits Hong Kong

Join our free newsletter for daily crypto updates!